An illustrative image of a person holding a medical syringe and a Covid-19 vaccine vial in front of the Moderna logo displayed on a screen. (Photo by Artur Widak/NurPhoto via Getty Images)
\n\nModerna said Wednesday that its personalized mRNA cancer vaccine lowered the risk of melanoma returning or spreading in a late-stage trial.
\n\nThe positive results were a major breakthrough for this new type of cancer treatment and caused Moderna’s shares to rise as much as 160%.
\n\nModerna developed the vaccine with Merck and tested it together with Keytruda, a common immunotherapy treatment for melanoma.
\n\nIf regulators approve the vaccine, thousands of patients who have had high-risk melanoma tumors removed could benefit from it as soon as next year, Moderna President Stephen Hoge said.
\n\nChristina Merrill, creator of the CancerBuddy, joins LiveNOW from FOX to talk about an app to connect those dealing with cancer.
\n\nThis is the first successful late-stage trial for an mRNA cancer vaccine. The vaccine works by training a patient’s immune system to recognize and attack specific mutations in cancer cells. It is also the first study to show that adding another treatment to Keytruda worked better than Keytruda alone. Similar vaccines are being studied for…
Original source: https://www.livenowfox.com/tag/science
